Helen J Gogas
National and Kapodistrian University of Athens · 603 works · 35,206 citations · h-index 75
Top works
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
- Prognostic significance of autoimmunity during treatment of melanoma with interferon
- Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- Treatment Algorithms in Stage IV Melanoma
- Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- Next Generation of Immunotherapy for Melanoma
- Chemotherapy for metastatic melanoma